RAPT Therapeutics (RAPT) Reports Positive Topline Results from Phase 1b Trial of RPT193 Monotherapy in Atopic Dermatitis
Go back to RAPT Therapeutics (RAPT) Reports Positive Topline Results from Phase 1b Trial of RPT193 Monotherapy in Atopic Dermatitis| Raptor Technology Group, Inc. (NASDAQ: RAPT) | Delayed: 8.00 +0.14 (1.78%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $7.86 | 52 Week High | $0.02 | |||
| Open | $7.98 | 52 Week Low | $0.00 | |||
| Day High | $8.24 | P/E | N/A | |||
| Day Low | $7.97 | EPS | $0.00 | |||
| Volume | 227,950 | |||||
